The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing doses of deupirfenidone were assessed ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Oral nerandomilast doses of 9 mg and 18 mg were ...

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the ...